PT732929E - Utilização terapêutica de ''engodos'' de elementos cis in vivo - Google Patents

Utilização terapêutica de ''engodos'' de elementos cis in vivo Download PDF

Info

Publication number
PT732929E
PT732929E PT95900450T PT95900450T PT732929E PT 732929 E PT732929 E PT 732929E PT 95900450 T PT95900450 T PT 95900450T PT 95900450 T PT95900450 T PT 95900450T PT 732929 E PT732929 E PT 732929E
Authority
PT
Portugal
Prior art keywords
endogenous
decoys
binding
provides
transcription factor
Prior art date
Application number
PT95900450T
Other languages
English (en)
Inventor
Victor Joseph Dzau
Gary H Gibbons
Ryuichi Morishita
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22509818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT732929(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of PT732929E publication Critical patent/PT732929E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT95900450T 1993-10-29 1994-10-28 Utilização terapêutica de ''engodos'' de elementos cis in vivo PT732929E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14471793A 1993-10-29 1993-10-29

Publications (1)

Publication Number Publication Date
PT732929E true PT732929E (pt) 2008-08-26

Family

ID=22509818

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95900450T PT732929E (pt) 1993-10-29 1994-10-28 Utilização terapêutica de ''engodos'' de elementos cis in vivo

Country Status (8)

Country Link
US (5) US6774118B1 (pt)
EP (3) EP1340505A3 (pt)
AT (1) ATE395065T1 (pt)
DE (1) DE69435100D1 (pt)
DK (1) DK0732929T3 (pt)
ES (1) ES2307293T3 (pt)
PT (1) PT732929E (pt)
WO (1) WO1995011687A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435100D1 (de) * 1993-10-29 2008-06-26 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US6034234A (en) * 1994-11-17 2000-03-07 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient
EP0824918B1 (en) 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
US6946246B1 (en) 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
US7002003B1 (en) * 1998-07-30 2006-02-21 University Of South Florida Method for the inhibition of function of STAT transcription factors
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
ATE333506T1 (de) * 2000-08-30 2006-08-15 Univ North Carolina State Transgene pflanzen, die molekulare decoys enthalten, die den proteininhalt ändern
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
DE60225899T2 (de) * 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
US20030224992A1 (en) * 2002-03-15 2003-12-04 Praecis Pharmaceuticals Inc. Transcription factor modulators and uses thereof
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
TWI231312B (en) * 2002-04-26 2005-04-21 Anges Mg Inc Novel dumbbell decoy oligodeoxynucleotides and use thereof
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
US20040266712A1 (en) * 2003-04-08 2004-12-30 Mcevoy Leslie M. Selective inhibition of vascular smooth muscle cell proliferation
US20050164240A1 (en) * 2003-10-06 2005-07-28 Corgentech, Inc. E2F oligonucleotide decoy molecules
WO2005055804A2 (en) 2003-12-02 2005-06-23 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
WO2005079217A2 (en) * 2003-12-19 2005-09-01 University Of Cincinnati Oligonucleotide decoys and methods of use
WO2005062854A2 (en) 2003-12-19 2005-07-14 University Of Cincinnati Polyamides for nucleic acid delivery
US7981616B2 (en) 2004-02-27 2011-07-19 Musc Foundation For Research Development Enhanced detection of RNA using a panel of truncated gene-specific primers for reverse transcription
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1774025A4 (en) 2004-07-09 2009-09-16 Univ Pittsburgh IDENTIFYING MARKERS IN LUNG AND BREAST CANCER
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
EP1892293A4 (en) * 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
US20090227661A1 (en) * 2005-12-22 2009-09-10 Zhiguo Wang Transcription factor decoy oligodeoxynucleotides having multiple cis elements
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2127681A4 (en) 2007-02-16 2011-10-12 Anges Mg Inc THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION
SI2158316T1 (sl) 2007-05-11 2015-08-31 Adynxx Inc. Genska ekspresija in bolečina
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
CN102046208B (zh) 2008-03-28 2014-07-02 安琪士摩奇株式会社 包含转录因子诱饵作为活性成分的用于外部应用的组合物
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
US9700624B2 (en) 2012-05-10 2017-07-11 Adynxx, Inc. Formulations for the delivery of active ingredients
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
WO2015031628A1 (en) * 2013-08-28 2015-03-05 Oregon Health & Science University Synthetic oligonucleotides for detection of nucleic acid binding proteins
EP3626822A1 (en) 2014-08-15 2020-03-25 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US20180223280A1 (en) * 2015-10-23 2018-08-09 Rena Therapeutics Inc. Nucleic acid complex
WO2018067165A1 (en) * 2016-10-07 2018-04-12 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
DE69232722T2 (de) * 1991-08-23 2002-12-05 Univ Nebraska Lincoln Board Of Verfahren und zusammensetzungen für zelluläre reprogrammierung
AU3584993A (en) * 1992-01-27 1993-09-01 Trustees Of The University Of Pennsylvania, The Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
AU3609693A (en) * 1992-01-29 1993-09-01 Duke University Method of assaying for the oncogenic state of cells
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
CA2148258A1 (en) * 1992-10-29 1994-05-11 Nicholas Barrie La Thangue Transcription factor dp-1
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
ATE232731T1 (de) * 1993-10-29 2003-03-15 Shunichi Shiozawa Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen
DE69435100D1 (de) 1993-10-29 2008-06-26 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0824918B1 (en) * 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
DE60225899T2 (de) * 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
CA2467915A1 (en) * 2001-11-22 2003-05-30 Anges Mg, Inc. Compositions inhibiting rejection in organ transplantation and method of using the same
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
AU2002241343A1 (en) * 2002-03-29 2003-10-13 Anges Mg, Inc. Decoy compositions for treating and preventing brain diseases and disorders
WO2003099339A1 (fr) * 2002-05-29 2003-12-04 Anges Mg, Inc. Composition leurre pour traiter et prevenir une affection inflammatoire
WO2004060317A2 (en) * 2002-12-31 2004-07-22 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
EP1462111A1 (en) * 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Composition for inducing immunotolerance
US20040191779A1 (en) * 2003-03-28 2004-09-30 Jie Zhang Statistical analysis of regulatory factor binding sites of differentially expressed genes
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
JP2007512845A (ja) * 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides

Also Published As

Publication number Publication date
DK0732929T3 (da) 2008-09-01
US6821956B2 (en) 2004-11-23
US6774118B1 (en) 2004-08-10
US20040229833A1 (en) 2004-11-18
US20030186922A1 (en) 2003-10-02
DE69435100D1 (de) 2008-06-26
US20020128217A1 (en) 2002-09-12
WO1995011687A1 (en) 1995-05-04
ATE395065T1 (de) 2008-05-15
US20020052333A1 (en) 2002-05-02
EP1350514A2 (en) 2003-10-08
EP1350514A3 (en) 2004-07-07
EP0732929A4 (en) 2001-11-14
EP0732929B1 (en) 2008-05-14
EP1340505A3 (en) 2004-07-14
ES2307293T3 (es) 2008-11-16
EP0732929A1 (en) 1996-09-25
EP1340505A2 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
PT732929E (pt) Utilização terapêutica de ''engodos'' de elementos cis in vivo
ES2895652T3 (es) Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
CA2098849A1 (en) Control of gene expression by ionizing radiation
WO1998049300A3 (en) Truncated vegf-related proteins
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
DE60221572T2 (de) Kontrolle der genexpression durch verwendung eines komplexes aus einem oligonucleotid und einem regulatorischen peptid
FI925210A (fi) Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda
AU8435698A (en) Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
ATE208814T1 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere
WO2002066071A3 (en) Treatment of tissue fibrosis by blocking the sp1 transcription factor
WO2005089252B1 (en) Methods and compositions for the treatment of obesity
HUP9900060A2 (hu) Központi idegrendszeri axonnövekedés-modulátorok, ezeket tartalmazó készítmények, sejtek és eljárás az előállításukra, valamint felhasználásuk
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
EP1887083B1 (en) Use of the 5'UTR region of the ZAM retrotrasposon of D. melanogaster as "insulator" to guarantee transgene high expression levels
CN113181376A (zh) Htra2基因表达抑制剂在预防获得性感音神经性聋中的应用
HUP0100612A2 (hu) Gyógyászati hatóanyagok szkrínelésére alkalmas eljárás